董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Frances H. Arnold | 女 | Director | 69 | 27.15万美元 | 51.43 | 2026-02-27 |
| Rupert Vessey | 男 | Director | 60 | 未披露 | 5.76 | 2026-02-27 |
| Paul Parker | 男 | Director | 62 | 88.60万美元 | 2.47 | 2026-02-27 |
| Stéphane Bancel | 男 | Director | 53 | 22.15万美元 | 123.44 | 2026-02-27 |
| Jane Mendillo | 女 | Director | 67 | 22.15万美元 | 11.52 | 2026-02-27 |
| Michael Nally | 男 | Chief Executive Officer and Director | 50 | 552.77万美元 | 681.34 | 2026-02-27 |
| Marsha H. Fanucci | 女 | Director | 72 | 88.60万美元 | 3.29 | 2026-02-27 |
| Nancy A. Simonian | 女 | Director | 65 | 未披露 | 5.76 | 2026-02-27 |
| Noubar Afeyan | 男 | Chairperson of the Board | 63 | 22.15万美元 | 5801.03 | 2026-02-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sean Martin | 男 | Chief Legal Officer and General Counsel | 63 | 未披露 | 未持股 | 2026-02-27 |
| Laurie Lee | 女 | Chief Medical Officer | 59 | 未披露 | 未持股 | 2026-02-27 |
| Beth Grous | 女 | Chief People Officer | 58 | 未披露 | 未持股 | 2026-02-27 |
| Gevorg Grigoryan | 男 | Chief Technology Officer and Co-Founder | 45 | 229.55万美元 | 98.91 | 2026-02-27 |
| Jason Silvers | 男 | Chief Financial Officer and President | 54 | 221.92万美元 | 95.01 | 2026-02-27 |
| Aarif Khakoo | 男 | Chief Scientific Officer | 55 | 未披露 | 未持股 | 2026-02-27 |
| Michael Nally | 男 | Chief Executive Officer and Director | 50 | 552.77万美元 | 681.34 | 2026-02-27 |
董事简历
中英对照 | 中文 | 英文- Frances H. Arnold
-
Frances H. Arnold，自2016年起担任董事。她是加州理工学院化学工程、生物工程和生物化学的莱纳斯鲍林教授，自1986年以来一直在那里任教。阿诺德博士因开拓定向酶进化而获得诺贝尔化学奖（2018年）；她让Illumina公司用这些方法来制造用于替代能源、化学品和药物的酶。她是President科学技术顾问委员会的联合主席。她于2011年获得美国国家工程院查尔斯·斯塔克·德雷珀奖，2013年获得奥巴马总统颁发的美国国家技术与创新奖章，2016年获得千年科技奖。她被选入美国国家科学院、医学院和工程院，并于2019年被教皇方济各任命为宗座科学院院士。阿诺德博士是62项美国专利的共同发明人。Arnold目前担任Alphabet Inc.和以下私人控股公司的董事：Provivi（农业和害虫管理公司）、Aralez Bio（生物工程公司）、Resilience（生物制药制造公司）、Generate Biomedicines（药物生产公司）和Altos Labs（生物技术公司）。她在普林斯顿大学获得机械和航空航天工程学士学位，在加州大学伯克利分校获得化学工程博士学位。她担任David and Lucile Packard Foundation Fellowships in Science and Engineering的顾问小组主席，也是Gordon Research Conferences的董事会副主席。
Frances H. Arnold manages a research group, is the Linus Pauling Professor of Chemical Engineering, Bioengineering and Biochemistry, and is the Director of the Donna and Benjamin M. Rosen Bioengineering Center, all at the California Institute of Technology. She joined the California Institute of Technology in 1986 and has served as a Visiting Associate, Assistant Professor, Professor, and Director. Frances's laboratory focuses on protein engineering by directed evolution, and enzyme design and engineering using artificial intelligence, with applications in alternative energy, chemicals, and medicine. Frances is the recipient of numerous honors, including the Nobel Prize in Chemistry, the Millennium Technology Prize, induction into the National Inventors Hall of Fame, Fellow of the National Academy of Inventors, the ENI Prize in Renewable and Nonconventional Energy, the U.S. National Medal of Technology and Innovation, and the Charles Stark Draper Prize of the U.S. National Academy of Engineering. Frances holds a Bachelor of Science degree in mechanical and aerospace engineering from Princeton University and a Doctoral degree in chemical engineering from the University of California, Berkeley. - Frances H. Arnold，自2016年起担任董事。她是加州理工学院化学工程、生物工程和生物化学的莱纳斯鲍林教授，自1986年以来一直在那里任教。阿诺德博士因开拓定向酶进化而获得诺贝尔化学奖（2018年）；她让Illumina公司用这些方法来制造用于替代能源、化学品和药物的酶。她是President科学技术顾问委员会的联合主席。她于2011年获得美国国家工程院查尔斯·斯塔克·德雷珀奖，2013年获得奥巴马总统颁发的美国国家技术与创新奖章，2016年获得千年科技奖。她被选入美国国家科学院、医学院和工程院，并于2019年被教皇方济各任命为宗座科学院院士。阿诺德博士是62项美国专利的共同发明人。Arnold目前担任Alphabet Inc.和以下私人控股公司的董事：Provivi（农业和害虫管理公司）、Aralez Bio（生物工程公司）、Resilience（生物制药制造公司）、Generate Biomedicines（药物生产公司）和Altos Labs（生物技术公司）。她在普林斯顿大学获得机械和航空航天工程学士学位，在加州大学伯克利分校获得化学工程博士学位。她担任David and Lucile Packard Foundation Fellowships in Science and Engineering的顾问小组主席，也是Gordon Research Conferences的董事会副主席。
- Frances H. Arnold manages a research group, is the Linus Pauling Professor of Chemical Engineering, Bioengineering and Biochemistry, and is the Director of the Donna and Benjamin M. Rosen Bioengineering Center, all at the California Institute of Technology. She joined the California Institute of Technology in 1986 and has served as a Visiting Associate, Assistant Professor, Professor, and Director. Frances's laboratory focuses on protein engineering by directed evolution, and enzyme design and engineering using artificial intelligence, with applications in alternative energy, chemicals, and medicine. Frances is the recipient of numerous honors, including the Nobel Prize in Chemistry, the Millennium Technology Prize, induction into the National Inventors Hall of Fame, Fellow of the National Academy of Inventors, the ENI Prize in Renewable and Nonconventional Energy, the U.S. National Medal of Technology and Innovation, and the Charles Stark Draper Prize of the U.S. National Academy of Engineering. Frances holds a Bachelor of Science degree in mechanical and aerospace engineering from Princeton University and a Doctoral degree in chemical engineering from the University of California, Berkeley.
- Rupert Vessey
-
Rupert Vessey目前是Celgene全球研究与早期开发总裁，并有望在对Celgene的最终收购完成后在百时美施贵宝（Bristol-Myers Squibb）担任该职位。 在Celgene任职期间，Vessey博士从2017年4月开始担任Juno Therapeutics董事会成员，直到2018年3月被Celgene收购为止。在加入Celgene之前，Vessey博士在默克公司担任过各种研发高级管理职务。 Vessey博士拥有牛津大学生理科学硕士学位和临床医学BMCh学位，在那里他在牛津分子医学研究所完成了他的博士学位，并在英国的多家医院进行了额外的临床培训。 他是英国伦敦皇家内科医学院的成员。 他还是私人疗法公司Pharmakea的董事会成员。
Rupert Vessey has served as a member of board of directors since June 2024. Dr. Vessey joined Flagship Pioneering as Executive Partner and Chief Scientist in July 2023 after retiring from Bristol Myers Squibb Company (NYSE: BMY) ("Bristol Meyers Squibb"), where he had served as the President of Research and Early Development since 2019. Prior to joining Bristol Myers Squibb, he was President of Global Research and Early Development at Celgene Corporation from 2015 to 2019. Before joining Celgene Corporation, Dr. Vessey held vario research and development senior management positions during his 10 year tenure at Merck. Dr. Vessey has also served as a member of the board of directors of Bio Techne Corp (NASDAQ: TECH) since July 2019. He graduated from the University of Oxford with degrees in physiological sciences (B.A., M.A.), clinical medicine (B.M., B.Ch.) and a Doctor of Philosophy (DPhil) in molecular immunology. - Rupert Vessey目前是Celgene全球研究与早期开发总裁，并有望在对Celgene的最终收购完成后在百时美施贵宝（Bristol-Myers Squibb）担任该职位。 在Celgene任职期间，Vessey博士从2017年4月开始担任Juno Therapeutics董事会成员，直到2018年3月被Celgene收购为止。在加入Celgene之前，Vessey博士在默克公司担任过各种研发高级管理职务。 Vessey博士拥有牛津大学生理科学硕士学位和临床医学BMCh学位，在那里他在牛津分子医学研究所完成了他的博士学位，并在英国的多家医院进行了额外的临床培训。 他是英国伦敦皇家内科医学院的成员。 他还是私人疗法公司Pharmakea的董事会成员。
- Rupert Vessey has served as a member of board of directors since June 2024. Dr. Vessey joined Flagship Pioneering as Executive Partner and Chief Scientist in July 2023 after retiring from Bristol Myers Squibb Company (NYSE: BMY) ("Bristol Meyers Squibb"), where he had served as the President of Research and Early Development since 2019. Prior to joining Bristol Myers Squibb, he was President of Global Research and Early Development at Celgene Corporation from 2015 to 2019. Before joining Celgene Corporation, Dr. Vessey held vario research and development senior management positions during his 10 year tenure at Merck. Dr. Vessey has also served as a member of the board of directors of Bio Techne Corp (NASDAQ: TECH) since July 2019. He graduated from the University of Oxford with degrees in physiological sciences (B.A., M.A.), clinical medicine (B.M., B.Ch.) and a Doctor of Philosophy (DPhil) in molecular immunology.
- Paul Parker
-
Paul Parker，自2020年4月起担任Thermo Fisher Scientific Inc.的战略和企业发展高级副总裁，负责企业战略、并购、整合管理、企业社会责任、政府关系和数字营销。Parker在多个行业和地区拥有35年的并购银行经验。在加入Thermo Fisher之前，Parker从2014年8月到2020年3月担任Goldman Sachs & Co.的全球并购集团联席主席，也担任Goldman Sachs & Co.的合伙委员会和投资银行高级领导委员会的成员。在加入高盛之前，Parker于2008年9月至2014年7月担任巴克莱（Barclays）的董事长和全球并购主管，并于2012年6月至2013年10月承担全球企业融资的责任。他还曾任职巴克莱美洲管理委员会。从1995年到2008年，Parker在雷曼兄弟担任投资银行家，担任多个领导职位，包括2003年到2008年担任美国并购负责人，2008年担任全球并购主席和负责人。在巴克莱（Barclays）和雷曼兄弟（Lehman Brothers）任职期间，帕克曾在投资银行部门的执行委员会任职。
Paul Parker has served as a member of board of directors since June 2025. Mr. Parker has also served as managing partner of capital solutions and value realization at Flagship Pioneering since September 2024. Previoly, Mr. Parker held multiple leadership roles at Thermo Fisher Scientific Inc. (NYSE: TMO) from April 2020 to Augt 2024, most recently as senior vice president, head of strategy and corporate development, as ll as at Goldman Sachs from Augt 2014 to February 2020, where he served as co chairman of the Global Mergers and Acquisitions Group. Mr. Parker previoly served as a member of the Board of The Clorox Company (NYSE: CLX) from November 2020 to November 2024. He earned an M.B.A. with distinction from Harvard Biness School and a B.A. in international studies from the University of North Carolina at Chapel Hill. - Paul Parker，自2020年4月起担任Thermo Fisher Scientific Inc.的战略和企业发展高级副总裁，负责企业战略、并购、整合管理、企业社会责任、政府关系和数字营销。Parker在多个行业和地区拥有35年的并购银行经验。在加入Thermo Fisher之前，Parker从2014年8月到2020年3月担任Goldman Sachs & Co.的全球并购集团联席主席，也担任Goldman Sachs & Co.的合伙委员会和投资银行高级领导委员会的成员。在加入高盛之前，Parker于2008年9月至2014年7月担任巴克莱（Barclays）的董事长和全球并购主管，并于2012年6月至2013年10月承担全球企业融资的责任。他还曾任职巴克莱美洲管理委员会。从1995年到2008年，Parker在雷曼兄弟担任投资银行家，担任多个领导职位，包括2003年到2008年担任美国并购负责人，2008年担任全球并购主席和负责人。在巴克莱（Barclays）和雷曼兄弟（Lehman Brothers）任职期间，帕克曾在投资银行部门的执行委员会任职。
- Paul Parker has served as a member of board of directors since June 2025. Mr. Parker has also served as managing partner of capital solutions and value realization at Flagship Pioneering since September 2024. Previoly, Mr. Parker held multiple leadership roles at Thermo Fisher Scientific Inc. (NYSE: TMO) from April 2020 to Augt 2024, most recently as senior vice president, head of strategy and corporate development, as ll as at Goldman Sachs from Augt 2014 to February 2020, where he served as co chairman of the Global Mergers and Acquisitions Group. Mr. Parker previoly served as a member of the Board of The Clorox Company (NYSE: CLX) from November 2020 to November 2024. He earned an M.B.A. with distinction from Harvard Biness School and a B.A. in international studies from the University of North Carolina at Chapel Hill.
- Stéphane Bancel
-
St é phane Bancel自2019年9月起担任董事会成员。Bancel先生自2011年10月起担任Moderna的首席执行官，并自2013年5月起担任Flagship Pioneering的风险合伙人。在加入Moderna之前，Bancel先生曾在法国诊断公司bioM é rieux SA担任了五年的首席执行官。2000年7月至2006年3月，他在礼来公司担任过多个职务，包括担任比利时董事总经理，以及全球制造战略和供应链执行董事。在加入礼来之前，Bancel先生曾担任生物梅里埃公司的亚太区销售和市场总监。Bancel先生自2011年3月起担任Moderna董事会成员，并于2013年6月至2021年6月担任Qiagen N.V.（NYSE：QGEN）董事会成员。班塞尔先生于2022年被提名为法国最高认可的军团荣誉骑士，并于2024年当选为美国国家工程院院士。Bancel先生拥有哈佛BINCE学校的工商管理硕士学位、明尼苏达大学化学工程理学硕士学位和巴黎中央大学工学硕士学位。
Stéphane Bancel has served as a member of board of directors since September 2019. Mr. Bancel has served as Moderna's chief executive officer since October 2011 and a venture partner at Flagship Pioneering since May 2013. Before joining Moderna, Mr. Bancel served for five years as CEO of the French diagnostics company bioMérieux SA. From July 2000 to March 2006, he served in vario roles at Eli Lilly and Company, including as Managing Director, Belgium, and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Eli Lilly, Mr. Bancel served as Asia Pacific Sales and Marketing Director for bioMérieux. Mr. Bancel has been a member of Moderna's board of directors since March 2011 and of Qiagen N.V.'s (NYSE: QGEN) board of directors from June 2013 to June 2021. Mr. Bancel was nominated Chevalier of the Legion d'honneur in 2022, the highest recognition in France, and was elected to the U.S. National Academy of Engineering in 2024. Mr. Bancel holds an M.B.A. from Harvard Biness School, a Master of Science degree in chemical engineering from the University of Minnesota and Master of Engineering degree from cole Centrale Paris. - St é phane Bancel自2019年9月起担任董事会成员。Bancel先生自2011年10月起担任Moderna的首席执行官，并自2013年5月起担任Flagship Pioneering的风险合伙人。在加入Moderna之前，Bancel先生曾在法国诊断公司bioM é rieux SA担任了五年的首席执行官。2000年7月至2006年3月，他在礼来公司担任过多个职务，包括担任比利时董事总经理，以及全球制造战略和供应链执行董事。在加入礼来之前，Bancel先生曾担任生物梅里埃公司的亚太区销售和市场总监。Bancel先生自2011年3月起担任Moderna董事会成员，并于2013年6月至2021年6月担任Qiagen N.V.（NYSE：QGEN）董事会成员。班塞尔先生于2022年被提名为法国最高认可的军团荣誉骑士，并于2024年当选为美国国家工程院院士。Bancel先生拥有哈佛BINCE学校的工商管理硕士学位、明尼苏达大学化学工程理学硕士学位和巴黎中央大学工学硕士学位。
- Stéphane Bancel has served as a member of board of directors since September 2019. Mr. Bancel has served as Moderna's chief executive officer since October 2011 and a venture partner at Flagship Pioneering since May 2013. Before joining Moderna, Mr. Bancel served for five years as CEO of the French diagnostics company bioMérieux SA. From July 2000 to March 2006, he served in vario roles at Eli Lilly and Company, including as Managing Director, Belgium, and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Eli Lilly, Mr. Bancel served as Asia Pacific Sales and Marketing Director for bioMérieux. Mr. Bancel has been a member of Moderna's board of directors since March 2011 and of Qiagen N.V.'s (NYSE: QGEN) board of directors from June 2013 to June 2021. Mr. Bancel was nominated Chevalier of the Legion d'honneur in 2022, the highest recognition in France, and was elected to the U.S. National Academy of Engineering in 2024. Mr. Bancel holds an M.B.A. from Harvard Biness School, a Master of Science degree in chemical engineering from the University of Minnesota and Master of Engineering degree from cole Centrale Paris.
- Jane Mendillo
-
Jane Mendillo自2022年12月起担任董事会成员。Mendillo女士在捐赠基金和投资管理领域工作了30多年。作为2008年至2014年哈佛管理公司的首席执行官，她在广泛的公共和私人市场管理着哈佛大学约370亿美元的全球捐赠基金和相关资产。Mendillo女士在莱斯利学院担任了六年的首席投资官。在此之前，她在哈佛管理公司担任了15年的各种投资职务。在她职业生涯的早期，她是贝恩公司的管理顾问，曾在耶鲁大学投资办公室工作。Mendillo女士还于2016年4月至2025年4月担任Lazard公司（纽约证券交易所代码：LAZ）的董事，并于2016年6月至2022年6月担任通用汽车公司（纽约证券交易所代码：GM）的董事。她还担任Old Mountain Private TRT公司的Trtee，SpringBoard Capital投资委员会主席。Mendillo女士拥有耶鲁大学管理学院的工商管理硕士学位和耶鲁大学的学士学位。
Jane Mendillo has served as a member of board of directors since December 2022. Ms. Mendillo has spent over 30 years in the fields of endowment and investment management. As the CEO of the Harvard Management Company from 2008 to 2014, she managed Harvard University's approximately $37 billion global endowment and related assets across a wide range of public and private markets. Ms. Mendillo was previoly the chief investment officer at llesley College for six years. Prior to that, she spent 15 years at the Harvard Management Company in vario investment roles. Earlier in her career she was a management consultant at Bain & Co. and worked at the Yale Investment Office. Ms. Mendillo has also served as director of Lazard Inc. (NYSE: LAZ) from April 2016 to April 2025 and served as director of General Motors Co (NYSE: GM) from June 2016 to June 2022. She also serves as Trtee to the Old Mountain Private Trt Company, and Chair of the Investment Committee of Springboard Capital. Ms. Mendillo holds an M.B.A. from the Yale School of Management and a B.A. from Yale College. - Jane Mendillo自2022年12月起担任董事会成员。Mendillo女士在捐赠基金和投资管理领域工作了30多年。作为2008年至2014年哈佛管理公司的首席执行官，她在广泛的公共和私人市场管理着哈佛大学约370亿美元的全球捐赠基金和相关资产。Mendillo女士在莱斯利学院担任了六年的首席投资官。在此之前，她在哈佛管理公司担任了15年的各种投资职务。在她职业生涯的早期，她是贝恩公司的管理顾问，曾在耶鲁大学投资办公室工作。Mendillo女士还于2016年4月至2025年4月担任Lazard公司（纽约证券交易所代码：LAZ）的董事，并于2016年6月至2022年6月担任通用汽车公司（纽约证券交易所代码：GM）的董事。她还担任Old Mountain Private TRT公司的Trtee，SpringBoard Capital投资委员会主席。Mendillo女士拥有耶鲁大学管理学院的工商管理硕士学位和耶鲁大学的学士学位。
- Jane Mendillo has served as a member of board of directors since December 2022. Ms. Mendillo has spent over 30 years in the fields of endowment and investment management. As the CEO of the Harvard Management Company from 2008 to 2014, she managed Harvard University's approximately $37 billion global endowment and related assets across a wide range of public and private markets. Ms. Mendillo was previoly the chief investment officer at llesley College for six years. Prior to that, she spent 15 years at the Harvard Management Company in vario investment roles. Earlier in her career she was a management consultant at Bain & Co. and worked at the Yale Investment Office. Ms. Mendillo has also served as director of Lazard Inc. (NYSE: LAZ) from April 2016 to April 2025 and served as director of General Motors Co (NYSE: GM) from June 2016 to June 2022. She also serves as Trtee to the Old Mountain Private Trt Company, and Chair of the Investment Committee of Springboard Capital. Ms. Mendillo holds an M.B.A. from the Yale School of Management and a B.A. from Yale College.
- Michael Nally
-
Michael Nally自2021年3月起担任首席执行官和公司董事会（“董事会”）成员，并于2021年3月至2026年2月担任总裁。Nally先生还自2021年3月起担任Flagship Pioneering的首席执行官合伙人。Previoly，Nally先生曾于2003年8月至2021年3月在默克制药公司（NYSE：MRK）担任多个职务，最近一次是在2019年1月至2021年3月担任执行副总裁兼首席营销官。此外，Nally先生自2021年2月起担任PPG Indtries，Inc.（纽约证券交易所代码：PPG）（“PPG Indtries”）的董事会成员。Nally先生拥有哈佛大学Biness School的工商管理硕士学位、伦敦经济学院的会计和金融学位以及米德尔伯里学院的经济学学士学位。
Michael Nally has served as Chief Executive Officer and as a member of board of directors since March 2021, and served as President from March 2021 to February 2026. Mr. Nally has also served as a CEO Partner at Flagship Pioneering since March 2021. Previoly, Mr. Nally served in multiple roles at Merck & Co., Inc. (NYSE: MRK) from Augt 2003 to March 2021, including most recently as executive vice president and chief marketing officer from January 2019 until March 2021. Additionally, Mr. Nally has served as a member of the board of directors for PPG Indtries, Inc. (NYSE: PPG) ("PPG Indtries") since February 2021. Mr. Nally holds an M.B.A. from Harvard Biness School, a degree in accounting and finance from the London School of Economics and a B.A. in economics from Middlebury College. - Michael Nally自2021年3月起担任首席执行官和公司董事会（“董事会”）成员，并于2021年3月至2026年2月担任总裁。Nally先生还自2021年3月起担任Flagship Pioneering的首席执行官合伙人。Previoly，Nally先生曾于2003年8月至2021年3月在默克制药公司（NYSE：MRK）担任多个职务，最近一次是在2019年1月至2021年3月担任执行副总裁兼首席营销官。此外，Nally先生自2021年2月起担任PPG Indtries，Inc.（纽约证券交易所代码：PPG）（“PPG Indtries”）的董事会成员。Nally先生拥有哈佛大学Biness School的工商管理硕士学位、伦敦经济学院的会计和金融学位以及米德尔伯里学院的经济学学士学位。
- Michael Nally has served as Chief Executive Officer and as a member of board of directors since March 2021, and served as President from March 2021 to February 2026. Mr. Nally has also served as a CEO Partner at Flagship Pioneering since March 2021. Previoly, Mr. Nally served in multiple roles at Merck & Co., Inc. (NYSE: MRK) from Augt 2003 to March 2021, including most recently as executive vice president and chief marketing officer from January 2019 until March 2021. Additionally, Mr. Nally has served as a member of the board of directors for PPG Indtries, Inc. (NYSE: PPG) ("PPG Indtries") since February 2021. Mr. Nally holds an M.B.A. from Harvard Biness School, a degree in accounting and finance from the London School of Economics and a B.A. in economics from Middlebury College.
- Marsha H. Fanucci
-
Marsha H. Fanucci，自2009年起，她一直担任董事。自2004年7月至2009年1月，她担任 Millennium Pharmaceuticals, Inc.的高级副总裁和首席财务官，负责公司战略，财务，财务规划和报表以及运营。在Millennium任职时，她还担任财务和公司战略部门副总裁，以及公司开发和战略部门的副总裁。此前，自1998年至2000年，她是 Genzyme Corporation的公司开发和战略部门的副总裁，这是一个生物技术公司。1987年至1998年，她任职于Arthur D. Little, Inc.，在该公司她最近的是担任副总裁和董事。她目前任职于 Momenta Pharmaceuticals, Inc. 和 Alnylam Pharmaceuticals, Inc.的董事会。她取得了 West Virginia University配药学学士学位，以及Northeastern University。工商管理学硕士学位。
Marsha H. Fanucci has been a member of board of directors since March 2025. Since 2009, Ms. Fanucci has been an independent consultant. From 2004 to 2009, she served as senior vice president and chief financial officer of Millennium Pharmaceuticals, Inc. ("Millennium"), which was subsequently acquired by Takeda Pharmaceuticals Company Limited (NYSE: TAK) ("Takeda"). She previoly served in vario other roles at Millennium, including as vice president, finance and corporate strategy and vice president, corporate development. Ms. Fanucci previoly served as a director of Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) from October 2015 to February 2025, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from December 2010 to September 2023, Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) from March 2019 to May 2023 and Forma Therapeutics Holdings, Inc. (NASDAQ: FMTX) from October 2014 to October 2022. Ms. Fanucci received her B.S. in pharmacy from st Virginia University and her M.B.A. from Northeastern University. - Marsha H. Fanucci，自2009年起，她一直担任董事。自2004年7月至2009年1月，她担任 Millennium Pharmaceuticals, Inc.的高级副总裁和首席财务官，负责公司战略，财务，财务规划和报表以及运营。在Millennium任职时，她还担任财务和公司战略部门副总裁，以及公司开发和战略部门的副总裁。此前，自1998年至2000年，她是 Genzyme Corporation的公司开发和战略部门的副总裁，这是一个生物技术公司。1987年至1998年，她任职于Arthur D. Little, Inc.，在该公司她最近的是担任副总裁和董事。她目前任职于 Momenta Pharmaceuticals, Inc. 和 Alnylam Pharmaceuticals, Inc.的董事会。她取得了 West Virginia University配药学学士学位，以及Northeastern University。工商管理学硕士学位。
- Marsha H. Fanucci has been a member of board of directors since March 2025. Since 2009, Ms. Fanucci has been an independent consultant. From 2004 to 2009, she served as senior vice president and chief financial officer of Millennium Pharmaceuticals, Inc. ("Millennium"), which was subsequently acquired by Takeda Pharmaceuticals Company Limited (NYSE: TAK) ("Takeda"). She previoly served in vario other roles at Millennium, including as vice president, finance and corporate strategy and vice president, corporate development. Ms. Fanucci previoly served as a director of Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) from October 2015 to February 2025, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from December 2010 to September 2023, Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) from March 2019 to May 2023 and Forma Therapeutics Holdings, Inc. (NASDAQ: FMTX) from October 2014 to October 2022. Ms. Fanucci received her B.S. in pharmacy from st Virginia University and her M.B.A. from Northeastern University.
- Nancy A. Simonian
-
Nancy A. Simonian，医学博士。2012年3月起担任公司董事。2012年7月起，担任专注于基因控制疗法的民营生命科学公司Syros Pharmaceuticals, Inc.的首席执行官。2001至2011年10月，她在Millennium Pharmaceuticals, Inc.（The Takeda Oncology Company）工作，最近一职是首席医务官和临床、医疗和监管事务部高级副总裁。1995至2001年，她在 Biogen now Biogen Idec工作，最近一职是临床研究副总裁，负责包括Avonex和Tysabri。在内的神经学和肿瘤学的临床开发和医疗事务。她之前任Personalized Medicine Coalition和上市生物科技公司ArQule, Inc.的董事。在涉足制药行业前，她是Massachusetts General Hospital和Harvard Medical School的教员，任神经学助理教授。她获得Princeton University生物学学士学位，以及 University of Pennsylvania Medical School医学博士学位。
Nancy A. Simonian has served as a member of board of directors since June 2024. She served as chief executive officer of Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) ("Syros") from June 2012 to December 2023 and served as a member of the board of directors until February 2025. From 2001 to October 2011, Dr. Simonian was employed by Takeda and at Millennium, prior to its acquisition by Takeda, most recently as chief medical officer and senior vice president of clinical, medical and regulatory affairs. She currently is a member of the board of directors of Bayer AG (BAYRY), Alltrna, Inc., a private biotechnology company, and of the Damon Runyon Cancer Research Foundation. She previoly served as a member of the board of directors of Seagen Inc. and Evelo Biosciences, Inc., each a publicly traded biotechnology company. Prior to joining the biotechnology indtry, Dr. Simonian was on the faculty of Massachetts General Hospital and Harvard Medical School as an assistant professor of neurology. She received a B.A. in biology from Princeton University and an M.D. from the University of Pennsylvania School of Medicine. - Nancy A. Simonian，医学博士。2012年3月起担任公司董事。2012年7月起，担任专注于基因控制疗法的民营生命科学公司Syros Pharmaceuticals, Inc.的首席执行官。2001至2011年10月，她在Millennium Pharmaceuticals, Inc.（The Takeda Oncology Company）工作，最近一职是首席医务官和临床、医疗和监管事务部高级副总裁。1995至2001年，她在 Biogen now Biogen Idec工作，最近一职是临床研究副总裁，负责包括Avonex和Tysabri。在内的神经学和肿瘤学的临床开发和医疗事务。她之前任Personalized Medicine Coalition和上市生物科技公司ArQule, Inc.的董事。在涉足制药行业前，她是Massachusetts General Hospital和Harvard Medical School的教员，任神经学助理教授。她获得Princeton University生物学学士学位，以及 University of Pennsylvania Medical School医学博士学位。
- Nancy A. Simonian has served as a member of board of directors since June 2024. She served as chief executive officer of Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) ("Syros") from June 2012 to December 2023 and served as a member of the board of directors until February 2025. From 2001 to October 2011, Dr. Simonian was employed by Takeda and at Millennium, prior to its acquisition by Takeda, most recently as chief medical officer and senior vice president of clinical, medical and regulatory affairs. She currently is a member of the board of directors of Bayer AG (BAYRY), Alltrna, Inc., a private biotechnology company, and of the Damon Runyon Cancer Research Foundation. She previoly served as a member of the board of directors of Seagen Inc. and Evelo Biosciences, Inc., each a publicly traded biotechnology company. Prior to joining the biotechnology indtry, Dr. Simonian was on the faculty of Massachetts General Hospital and Harvard Medical School as an assistant professor of neurology. She received a B.A. in biology from Princeton University and an M.D. from the University of Pennsylvania School of Medicine.
- Noubar Afeyan
-
Noubar Afeyan自2008年2月以来任公司董事。1999年以来，他一直担任Flagship Ventures运营合伙人兼首席执行官，这是他联合创立的早期阶段风险投资公司。自2000年以来，他任BG Medicine公司董事。自2007年以来，任 BIND Therapeutics 董事。他获得McGill大学化学工程学士学位，麻省理工学院生化工程博士学位。
Noubar Afeyan is a co founder and has served as the chairman of board of directors since 2018. In 1999, Dr. Afeyan founded Flagship Pioneering and serves as its Chief Executive Officer. Flagship Pioneering is an institutional platform for the creation, development and capitalization of pioneering biotechnology companies, with over 100 ventures founded and about $14 billion in assets under its management. Dr. Afeyan is co founder and has served as chairman of the board of Moderna, Inc. (NASDAQ: MRNA) ("Moderna") since 2012. He has previoly served on the boards of numero privately and publicly held companies, including Omega Therapeutics, Inc. (NASDAQ: OMGA) from July 2016 to August 2023 and Rubi Therapeutics, Inc. (NASDAQ: RUBY) from 2013 to November 2022. He received a Ph.D. in biochemical engineering from the Massachetts Institute of Technology and a B.S. in chemical engineering from McGill University. Dr. Afeyan was previoly a visiting lecturer of biness administration at Harvard Biness School and was previoly a senior lecturer at MIT's Sloan School of Management where he taught cses on technology entrepreneurship, innovation and leadership. - Noubar Afeyan自2008年2月以来任公司董事。1999年以来，他一直担任Flagship Ventures运营合伙人兼首席执行官，这是他联合创立的早期阶段风险投资公司。自2000年以来，他任BG Medicine公司董事。自2007年以来，任 BIND Therapeutics 董事。他获得McGill大学化学工程学士学位，麻省理工学院生化工程博士学位。
- Noubar Afeyan is a co founder and has served as the chairman of board of directors since 2018. In 1999, Dr. Afeyan founded Flagship Pioneering and serves as its Chief Executive Officer. Flagship Pioneering is an institutional platform for the creation, development and capitalization of pioneering biotechnology companies, with over 100 ventures founded and about $14 billion in assets under its management. Dr. Afeyan is co founder and has served as chairman of the board of Moderna, Inc. (NASDAQ: MRNA) ("Moderna") since 2012. He has previoly served on the boards of numero privately and publicly held companies, including Omega Therapeutics, Inc. (NASDAQ: OMGA) from July 2016 to August 2023 and Rubi Therapeutics, Inc. (NASDAQ: RUBY) from 2013 to November 2022. He received a Ph.D. in biochemical engineering from the Massachetts Institute of Technology and a B.S. in chemical engineering from McGill University. Dr. Afeyan was previoly a visiting lecturer of biness administration at Harvard Biness School and was previoly a senior lecturer at MIT's Sloan School of Management where he taught cses on technology entrepreneurship, innovation and leadership.
高管简历
中英对照 | 中文 | 英文- Sean Martin
Sean Martin于2017年从阿波罗教育集团公司加入百特，并于2010年至2017年担任高级副总裁，总法律顾问兼秘书。此前，他担任助理秘书-2010-2010年至2010年公司法副总裁兼副总裁 Amgen Inc.的商法总裁（2005年至2009年）。他还于2000年至2005年担任Fresenius Medical Care North America的副总裁兼副总法律顾问。Martin先生于1998年成为Foley＆Lardner LLP律师事务所的合伙人。 到2000年，并担任伊利诺伊州北区助理美国检察官八年。
Sean Martin has served as Chief Legal Officer and General Counsel since April 2022. Previoly, Mr. Martin served as general counsel and senior vice president at Baxter International Inc. (NYSE: BAX) from February 2017 to April 2022. Prior to that role, he was general counsel, senior vice president and secretary at Apollo Education Group, Inc. He also served as vice president for commercial law and corporate law at Amgen Inc. and vice president and deputy general counsel for litigation at Freseni Medical Care North America. Earlier in his career, Mr. Martin was a law firm partner at Foley & Lardner LLP and served as an Assistant U.S. Attorney in Chicago for eight years, prosecuting federal criminal cases. Mr. Martin holds a J.D. from Harvard Law School and a B.A. in history from the University of Michigan.- Sean Martin于2017年从阿波罗教育集团公司加入百特，并于2010年至2017年担任高级副总裁，总法律顾问兼秘书。此前，他担任助理秘书-2010-2010年至2010年公司法副总裁兼副总裁 Amgen Inc.的商法总裁（2005年至2009年）。他还于2000年至2005年担任Fresenius Medical Care North America的副总裁兼副总法律顾问。Martin先生于1998年成为Foley＆Lardner LLP律师事务所的合伙人。 到2000年，并担任伊利诺伊州北区助理美国检察官八年。
- Sean Martin has served as Chief Legal Officer and General Counsel since April 2022. Previoly, Mr. Martin served as general counsel and senior vice president at Baxter International Inc. (NYSE: BAX) from February 2017 to April 2022. Prior to that role, he was general counsel, senior vice president and secretary at Apollo Education Group, Inc. He also served as vice president for commercial law and corporate law at Amgen Inc. and vice president and deputy general counsel for litigation at Freseni Medical Care North America. Earlier in his career, Mr. Martin was a law firm partner at Foley & Lardner LLP and served as an Assistant U.S. Attorney in Chicago for eight years, prosecuting federal criminal cases. Mr. Martin holds a J.D. from Harvard Law School and a B.A. in history from the University of Michigan.
- Laurie Lee
劳里·李自2025年9月起担任首席医疗官。Previoly，Dr. Lee于2020年4月至2025年9月在CSL Behring担任研发、移植和免疫学副总裁。在加入CSL Behring之前，Lee博士曾在葛兰素史克（GSK）担任多个职务，包括担任研发副总裁和药物开发领导者。Lee博士是儿科、过敏症和免疫学领域的董事会认证医师。她在俄亥俄州立大学医学院获得医学博士学位，在圣母大学获得生物学学士学位。李医生在哥伦布儿童医院完成了住院治疗，并在杜克大学医学中心完成了过敏和免疫学研究金，随后她加入了儿科学院。
Laurie Lee has served as Chief Medical Officer since September 2025. Previoly, Dr. Lee served as vice president of research and development, transplant and immunology, at CSL Behring from April 2020 to September 2025. Prior to joining CSL Behring, Dr. Lee served in multiple roles at GlaxoSmithKline plc (GSK), including as vice president of research and development and medicine development leader. Dr. Lee is a board certified physician in pediatrics, allergy and immunology. She earned her M.D. from the Ohio State University College of Medicine, and her B.S. in biology from the University of Notre Dame. Dr. Lee completed a residency at Columb Children's Hospital and fellowship in allergy and immunology at Duke University Medical Center, where she subsequently joined the pediatrics faculty.- 劳里·李自2025年9月起担任首席医疗官。Previoly，Dr. Lee于2020年4月至2025年9月在CSL Behring担任研发、移植和免疫学副总裁。在加入CSL Behring之前，Lee博士曾在葛兰素史克（GSK）担任多个职务，包括担任研发副总裁和药物开发领导者。Lee博士是儿科、过敏症和免疫学领域的董事会认证医师。她在俄亥俄州立大学医学院获得医学博士学位，在圣母大学获得生物学学士学位。李医生在哥伦布儿童医院完成了住院治疗，并在杜克大学医学中心完成了过敏和免疫学研究金，随后她加入了儿科学院。
- Laurie Lee has served as Chief Medical Officer since September 2025. Previoly, Dr. Lee served as vice president of research and development, transplant and immunology, at CSL Behring from April 2020 to September 2025. Prior to joining CSL Behring, Dr. Lee served in multiple roles at GlaxoSmithKline plc (GSK), including as vice president of research and development and medicine development leader. Dr. Lee is a board certified physician in pediatrics, allergy and immunology. She earned her M.D. from the Ohio State University College of Medicine, and her B.S. in biology from the University of Notre Dame. Dr. Lee completed a residency at Columb Children's Hospital and fellowship in allergy and immunology at Duke University Medical Center, where she subsequently joined the pediatrics faculty.
- Beth Grous
Beth Gro自2023年4月起担任首席人事官。自2019年1月起，她还在SemperVirens风险投资公司担任兼职风险顾问，并自2015年9月起担任TripAdvisor基金会董事会成员。Previoly，Ms. Gro曾于2015年9月至2023年3月在TripAdvisor，Inc.（NASDAQ：TRIP）担任高级副总裁兼首席人事官。在担任该职务之前，她曾在纽昂斯通讯公司担任全球人类资源高级副总裁，并在赛诺菲 S.A.位于波士顿的枢纽担任副总裁兼人类资源主管。她拥有康奈尔大学的英语学士学位。
Beth Grous has served as Chief People Officer since April 2023. She has also served as a part time venture advisor at SemperVirens Venture Capital since January 2019 and has served on the board of directors of the Tripadvisor Foundation since September 2015. Previously, Ms. Grous served as the senior vice president and chief people officer at Tripadvisor, Inc. (NASDAQ: TRIP) from September 2015 to March 2023. Prior to that role, she served as senior vice president of global human resces at Nuance Communications, Inc., as ll as vice president and head of human resces at Sanofi S.A.'s Boston hub. She holds a B.A. in English from Cornell University.- Beth Gro自2023年4月起担任首席人事官。自2019年1月起，她还在SemperVirens风险投资公司担任兼职风险顾问，并自2015年9月起担任TripAdvisor基金会董事会成员。Previoly，Ms. Gro曾于2015年9月至2023年3月在TripAdvisor，Inc.（NASDAQ：TRIP）担任高级副总裁兼首席人事官。在担任该职务之前，她曾在纽昂斯通讯公司担任全球人类资源高级副总裁，并在赛诺菲 S.A.位于波士顿的枢纽担任副总裁兼人类资源主管。她拥有康奈尔大学的英语学士学位。
- Beth Grous has served as Chief People Officer since April 2023. She has also served as a part time venture advisor at SemperVirens Venture Capital since January 2019 and has served on the board of directors of the Tripadvisor Foundation since September 2015. Previously, Ms. Grous served as the senior vice president and chief people officer at Tripadvisor, Inc. (NASDAQ: TRIP) from September 2015 to March 2023. Prior to that role, she served as senior vice president of global human resces at Nuance Communications, Inc., as ll as vice president and head of human resces at Sanofi S.A.'s Boston hub. She holds a B.A. in English from Cornell University.
- Gevorg Grigoryan
Gevorg Grigoryan是联合创始人，自2018年公司成立以来一直担任首席技术官。自2011年以来，他还在达特茅斯学院担任过各种职务（2017年终身任职），在那里他进行研究，并在计算机科学、生物科学和化学系的教职员工中任职，专注于揭示将蛋白质序列、结构和功能联系起来的原理。Grigoryan博士在《自然》、《科学》和《PNAS》等主要期刊上撰写了50多篇同行评审出版物，并获得了Alfred P. Sloan基金会、美国国立卫生研究院、美国国家科学基金会和美国癌症协会的认可。他拥有麻省理工学院博士学位，并在巴尔的摩县马里兰大学获得计算机科学和生物化学学士学位。此外，他还在宾夕法尼亚大学完成了博士后培训。
Gevorg Grigoryan is co founder and has served as Chief Technology Officer since the founding of the company in 2018. He has also held vario appointments at Dartmouth College since 2011 (tenured in 2017), where he conducted research and served on the faculty in the Departments of Computer Science, Biological Sciences, and Chemistry, focing on uncovering the principles that link protein sequence, structure, and function. Dr. Grigoryan has authored over 50 peer revied publications in leading jnals including Nature, Science, and PNAS and has received recognition from the Alfred P. Sloan Foundation, National Institutes of Health, National Science Foundation, and the American Cancer Society. He holds a Ph.D. from the Massachetts Institute of Technology and earned his B.S. in computer science and biochemistry from the University of Maryland, Baltimore County. Additionally, he completed postdoctoral training at the University of Pennsylvania.- Gevorg Grigoryan是联合创始人，自2018年公司成立以来一直担任首席技术官。自2011年以来，他还在达特茅斯学院担任过各种职务（2017年终身任职），在那里他进行研究，并在计算机科学、生物科学和化学系的教职员工中任职，专注于揭示将蛋白质序列、结构和功能联系起来的原理。Grigoryan博士在《自然》、《科学》和《PNAS》等主要期刊上撰写了50多篇同行评审出版物，并获得了Alfred P. Sloan基金会、美国国立卫生研究院、美国国家科学基金会和美国癌症协会的认可。他拥有麻省理工学院博士学位，并在巴尔的摩县马里兰大学获得计算机科学和生物化学学士学位。此外，他还在宾夕法尼亚大学完成了博士后培训。
- Gevorg Grigoryan is co founder and has served as Chief Technology Officer since the founding of the company in 2018. He has also held vario appointments at Dartmouth College since 2011 (tenured in 2017), where he conducted research and served on the faculty in the Departments of Computer Science, Biological Sciences, and Chemistry, focing on uncovering the principles that link protein sequence, structure, and function. Dr. Grigoryan has authored over 50 peer revied publications in leading jnals including Nature, Science, and PNAS and has received recognition from the Alfred P. Sloan Foundation, National Institutes of Health, National Science Foundation, and the American Cancer Society. He holds a Ph.D. from the Massachetts Institute of Technology and earned his B.S. in computer science and biochemistry from the University of Maryland, Baltimore County. Additionally, he completed postdoctoral training at the University of Pennsylvania.
- Jason Silvers
Jason Silvers自2022年7月起担任首席财务官，自2026年2月起担任总裁。Previoly，Silvers博士于2002年8月至2022年6月期间，在高盛 Sachs & Co.（“高盛 Sachs”）担任过多个职务，并于2010年成为董事总经理，2014年成为合伙人。最近，他共同管理高盛Sachs在欧洲、中东和非洲的医疗保健投资银行业务。Silvers博士拥有耶鲁大学法学院的法学博士学位、约翰霍普金斯大学医学院的医学博士学位和布朗大学的化学学士学位。他还在杰克逊纪念医院完成了一年的神经外科住院医师，并被授予年度外科实习生荣誉。
Jason Silvers has served as Chief Financial Officer since July 2022 and as President since February 2026. Previoly, Dr. Silvers served in multiple roles at Goldman Sachs & Co. ("Goldman Sachs") from Augt 2002 to June 2022, where he became a managing director in 2010 and partner in 2014. Most recently, he co managed healthcare investment banking for Goldman Sachs in Europe, the Middle East and Africa. Dr. Silvers holds a J.D. from Yale Law School, an M.D. from the Johns Hopkins University School of Medicine and a B.S. in chemistry from Brown University. He also completed one year of a neurosurgical residency at Jackson Memorial Hospital and was awarded the Surgical Intern of the Year distinction.- Jason Silvers自2022年7月起担任首席财务官，自2026年2月起担任总裁。Previoly，Silvers博士于2002年8月至2022年6月期间，在高盛 Sachs & Co.（“高盛 Sachs”）担任过多个职务，并于2010年成为董事总经理，2014年成为合伙人。最近，他共同管理高盛Sachs在欧洲、中东和非洲的医疗保健投资银行业务。Silvers博士拥有耶鲁大学法学院的法学博士学位、约翰霍普金斯大学医学院的医学博士学位和布朗大学的化学学士学位。他还在杰克逊纪念医院完成了一年的神经外科住院医师，并被授予年度外科实习生荣誉。
- Jason Silvers has served as Chief Financial Officer since July 2022 and as President since February 2026. Previoly, Dr. Silvers served in multiple roles at Goldman Sachs & Co. ("Goldman Sachs") from Augt 2002 to June 2022, where he became a managing director in 2010 and partner in 2014. Most recently, he co managed healthcare investment banking for Goldman Sachs in Europe, the Middle East and Africa. Dr. Silvers holds a J.D. from Yale Law School, an M.D. from the Johns Hopkins University School of Medicine and a B.S. in chemistry from Brown University. He also completed one year of a neurosurgical residency at Jackson Memorial Hospital and was awarded the Surgical Intern of the Year distinction.
- Aarif Khakoo
AARIF KHAKOO自2026年1月起担任首席科学官。他还是斯坦福大学医学院的兼职临床副教授，自2011年4月起担任该职务。Previoly，Khakoo博士在2023年12月至2026年1月期间担任Scribe Therapeutics，Inc.的首席科学官和研发主管。在担任该职务之前，他于2019年2月至2023年7月担任Calico Life Sciences LLC的首席医疗官和药物开发主管。在其职业生涯的早期，Khakoo博士曾在安进公司担任高级研发职务。Khakoo博士获得了哥伦比亚大学Vagelos内科和外科医学院的医学博士学位，以及哥伦比亚Biness School的工商管理硕士学位。他在约翰霍普金斯大学湾景医疗中心完成了内科住院医师实习，并在约翰霍普金斯大学医学院完成了心血管医学研究金。
Aarif Khakoo has served as Chief Scientific Officer since January 2026. He is also an adjunct clinical associate professor at the Stanford University School of Medicine, a role he has held since April 2011. Previoly, Dr. Khakoo was chief scientific officer and head of research and development at Scribe Therapeutics, Inc. from December 2023 to January 2026. Prior to that role, he was chief medical officer and head of drug development at Calico Life Sciences LLC from February 2019 to July 2023. Earlier in his career, Dr. Khakoo served in senior research and development roles at Amgen Inc. Dr. Khakoo earned his M.D. from the Columbia University Vagelos College of Physicians and Surgeons, and his M.B.A. from Columbia Biness School. He completed his residency in internal medicine at Johns Hopkins Bayview Medical Center, and a fellowship in cardiovascular medicine at the Johns Hopkins University School of Medicine.- AARIF KHAKOO自2026年1月起担任首席科学官。他还是斯坦福大学医学院的兼职临床副教授，自2011年4月起担任该职务。Previoly，Khakoo博士在2023年12月至2026年1月期间担任Scribe Therapeutics，Inc.的首席科学官和研发主管。在担任该职务之前，他于2019年2月至2023年7月担任Calico Life Sciences LLC的首席医疗官和药物开发主管。在其职业生涯的早期，Khakoo博士曾在安进公司担任高级研发职务。Khakoo博士获得了哥伦比亚大学Vagelos内科和外科医学院的医学博士学位，以及哥伦比亚Biness School的工商管理硕士学位。他在约翰霍普金斯大学湾景医疗中心完成了内科住院医师实习，并在约翰霍普金斯大学医学院完成了心血管医学研究金。
- Aarif Khakoo has served as Chief Scientific Officer since January 2026. He is also an adjunct clinical associate professor at the Stanford University School of Medicine, a role he has held since April 2011. Previoly, Dr. Khakoo was chief scientific officer and head of research and development at Scribe Therapeutics, Inc. from December 2023 to January 2026. Prior to that role, he was chief medical officer and head of drug development at Calico Life Sciences LLC from February 2019 to July 2023. Earlier in his career, Dr. Khakoo served in senior research and development roles at Amgen Inc. Dr. Khakoo earned his M.D. from the Columbia University Vagelos College of Physicians and Surgeons, and his M.B.A. from Columbia Biness School. He completed his residency in internal medicine at Johns Hopkins Bayview Medical Center, and a fellowship in cardiovascular medicine at the Johns Hopkins University School of Medicine.
- Michael Nally
Michael Nally自2021年3月起担任首席执行官和公司董事会（“董事会”）成员，并于2021年3月至2026年2月担任总裁。Nally先生还自2021年3月起担任Flagship Pioneering的首席执行官合伙人。Previoly，Nally先生曾于2003年8月至2021年3月在默克制药公司（NYSE：MRK）担任多个职务，最近一次是在2019年1月至2021年3月担任执行副总裁兼首席营销官。此外，Nally先生自2021年2月起担任PPG Indtries，Inc.（纽约证券交易所代码：PPG）（“PPG Indtries”）的董事会成员。Nally先生拥有哈佛大学Biness School的工商管理硕士学位、伦敦经济学院的会计和金融学位以及米德尔伯里学院的经济学学士学位。
Michael Nally has served as Chief Executive Officer and as a member of board of directors since March 2021, and served as President from March 2021 to February 2026. Mr. Nally has also served as a CEO Partner at Flagship Pioneering since March 2021. Previoly, Mr. Nally served in multiple roles at Merck & Co., Inc. (NYSE: MRK) from Augt 2003 to March 2021, including most recently as executive vice president and chief marketing officer from January 2019 until March 2021. Additionally, Mr. Nally has served as a member of the board of directors for PPG Indtries, Inc. (NYSE: PPG) ("PPG Indtries") since February 2021. Mr. Nally holds an M.B.A. from Harvard Biness School, a degree in accounting and finance from the London School of Economics and a B.A. in economics from Middlebury College.- Michael Nally自2021年3月起担任首席执行官和公司董事会（“董事会”）成员，并于2021年3月至2026年2月担任总裁。Nally先生还自2021年3月起担任Flagship Pioneering的首席执行官合伙人。Previoly，Nally先生曾于2003年8月至2021年3月在默克制药公司（NYSE：MRK）担任多个职务，最近一次是在2019年1月至2021年3月担任执行副总裁兼首席营销官。此外，Nally先生自2021年2月起担任PPG Indtries，Inc.（纽约证券交易所代码：PPG）（“PPG Indtries”）的董事会成员。Nally先生拥有哈佛大学Biness School的工商管理硕士学位、伦敦经济学院的会计和金融学位以及米德尔伯里学院的经济学学士学位。
- Michael Nally has served as Chief Executive Officer and as a member of board of directors since March 2021, and served as President from March 2021 to February 2026. Mr. Nally has also served as a CEO Partner at Flagship Pioneering since March 2021. Previoly, Mr. Nally served in multiple roles at Merck & Co., Inc. (NYSE: MRK) from Augt 2003 to March 2021, including most recently as executive vice president and chief marketing officer from January 2019 until March 2021. Additionally, Mr. Nally has served as a member of the board of directors for PPG Indtries, Inc. (NYSE: PPG) ("PPG Indtries") since February 2021. Mr. Nally holds an M.B.A. from Harvard Biness School, a degree in accounting and finance from the London School of Economics and a B.A. in economics from Middlebury College.